Edit
Capstan Therapeutics
https://www.capstantx.com/Last activity: 05.03.2026
Active - Reference to AbbVie
Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $175M
Founded date: 2021
Investors 3
| Date | Name | Website |
| 13.04.2024 | Vida Ventu... | vidaventur... |
| 23.03.2024 | Forbion | forbion.co... |
| 30.08.2023 | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.03.2024 | Series B | $175M | Forbion |
Mentions in press and media 17
| Date | Title | Description |
| 05.03.2026 | ImmunoScape Signs Clinical Trial MOU With U.S. Cancer Center And Secures Strategic Investment From Leonardo DiCaprio | ImmunoScape, a Singapore-headquartered biotechnology company developing next-generation T cell receptor (TCR) based cancer immunotherapies, announced that it has signed a memorandum of understanding with a leading National Cancer Institute-... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 10.01.2026 | UPenn, BioNTech, And Osage University Partners Launch $50 Million Seed Fund To Back Penn Life Science Startups | The University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a dedicated venture fund focused on early-stage life scienc... |
| 02.07.2025 | AbbVie купит Capstan Therapeutics для развития CAR-T терапии | - |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit. • Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 30.06.2025 | AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology | - |
| 11.06.2025 | Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease | - |
| 11.06.2025 | Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease | - CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells - mRNA-based approach is designed to achieve rapid, deep, and transient B cell depletion without the need for... |
| 03.03.2025 | Forbion Expands US Presence with the Appointment of Regina Salvat, PhD, as Principal in the Boston Office | Naarden, The Netherlands - 03 March 2025 - Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. This strategic hire underscores our commitment to strengthening our presence in the United S... |
Show more